期刊文献+

75岁以上晚期非小细胞肺癌泽菲单药一线方案治疗37例 被引量:1

First-line Chemotherapy with Single-agent of Gemcitabine for 37 Cases with Advanced Nonsmall Cell Cancer over 75 Years Old
原文传递
导出
摘要 [目的]探讨高龄晚期非小细胞肺癌(NSCLC)吉西他滨单药治疗的疗效。[方法]37例75岁以上晚期NSCLC以吉西他滨单药为一线方案,剂量1000mg/m2,静脉滴注,d1、8,每28d为1个周期。[结果]可评价疗效者CR1例,PR9例,SD13例,PD8例,有效率(RR)32.3%,疾病控制率(DCR)74.2%,1年生存率45.2%(14/31),中位疾病进展时间5个月,平均疾病进展时间4.6个月。[结论]吉西他滨单药一线方案治疗75岁以上晚期NSCLC具有良好耐受性,部分患者可显著改善生命质量。
出处 《肿瘤学杂志》 CAS 2008年第11期894-895,共2页 Journal of Chinese Oncology
  • 相关文献

参考文献4

  • 1杨玲,李连弟,陈育德,Donald Maxwell Parkin.中国肺癌死亡趋势分析及发病、死亡的估计与预测[J].中国肺癌杂志,2005,8(4):274-278. 被引量:168
  • 2Wasil T, Lichtman SM. Clinical pharmacology issues relevant to the dosing and toxicity of chemotherapy drugs in the elderly[J]. Oncologist, 2005, 10(8):602-612.
  • 3Gridelli C, Cigolari S, Gallo C, et al. Activity and toxicity of gemcitabine and gemcitabine+vinorelbine in advanced non-small-cell lung cancer elderly patients phase Ⅱ data from the muhicenter Italian lung cancer in the elderly study (MILES) randomized trial[J]. Lung Cancer, 2001, 31 (2-3):277-284.
  • 4Gridelli C, Perrone F, Cigolari S, et al. The MILES (Multicenter Italian Lung Cancer in the Elderly Study) phase Ⅲ trial:gemcitabine +vinorelbine vs vinorelbine and vs gemcitabine in elderly advanced NSCLC patients[C]. Proc Am Soc Clin Oncol, 2001, 20:230.

二级参考文献23

  • 1李连弟,鲁凤珠.1990—1992年中国恶性肿瘤死亡流行分布情况分析[J].中华肿瘤杂志,1996,18(6):403-407. 被引量:227
  • 2李连弟,鲁凤珠,张思维,牧人,孙秀娣,皇甫小梅,孙杰,周有尚,欧阳宁慧,饶克勤,陈育德,孙爱明,薛志福,夏毅.中国恶性肿瘤死亡率20年变化趋势和近期预测分析[J].中华肿瘤杂志,1997,19(1):3-9. 被引量:869
  • 3Jensen OM, Esteve J, Moller H, et al. Cancer in the European Community and its member states. Eur J Cancer, 1990, 26(11-12): 1167-1256. Erratum in: Eur J Cancer, 1991,27 (12):1717.
  • 4European Network of Cancer Registries (ENCR). (2001) EURO CIM version 4. 0. European Incidence Database V2. 3. Lyon:IARC Press,2001.
  • 5Bray F, Sankila R, Ferlay J, et al. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer,2002,38(1): 99-166.
  • 6Yang L, Parkin DM, Ferlay J, et al. Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev, 2005,14(1): 243-250.
  • 7International Agency for Research on Cancer. IARC monographs on the Tobacco Smoke and Involuntary Smoking (Vol. 83). Lyon:IARC Press,2004.
  • 8Liu BQ, Peto R, Chen ZM, et al. Emerging tobacco hazards in China: 1. Retrospective proportional mortality study of one million deaths. BMJ,1998,317(7170) : 1411-1422.
  • 9Clinical Trial Service Unit, Oxford University. Emerging Tobacco Hazards in China. http:∥rum. ctsu. ox. ac. uk/tobacco.
  • 10Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide, Version 2. 0. IARC CancerBase No. 5. Lyon: IARC Press,2004.

共引文献167

同被引文献6

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部